natgillin/translations-raw huggingface dataset:
The pharmacokinetics of docetaxel have been evaluated in cancer patients after administration of 20- 115 mg/m2 in phase I studies.
Farmakokinetiko docetaksela so ocenili pri onkoloških bolnikih po uporabi 20 mg/m2-115 mg/m2 v študijah I. faze.
The pharmacokinetics of docetaxel have been evaluated in cancer patients after administration of 20-115 mg/m2 in phase I studies.
Farmakokinetiko docetaksela so ocenili pri onkoloških bolnikih po uporabi 20–115 mg/m2 v študijah I. faze.
The pharmacokinetics of docetaxel, doxorubicin and cyclophosphamide were not influenced by their co- administration.
Docetaksel, doksorubicin in ciklofosfamid pri sočasni aplikaciji ne vplivajo na farmakokinetiko drug drugega.
The pharmacokinetics of dolutegravir in 10 antiretroviral treatment-experienced HIV-1 infected adolescents (12 to <18 years of age) showed that Tivicay 50 mg once daily oral dosage resulted in dolutegravir exposure comparable to that observed in adults who received Tivicay 50 mg orally once daily.
Farmakokinetika dolutegravirja pri 10 mladostnikih (starih od 12 do < 18 let), ki so bili okuženi s HIV-1 in so predhodno že prejemali protiretrovirusno zdravljenje, je pokazala, da peroralni odmerek 50 mg zdravila Tivicay enkrat na dan doseže izpostavljenost dolutegravirju, ki je primerljiva izpostavljenosti odraslih med jemanjem peroralnega odmerka 50 mg zdravila Tivicay enkrat na dan.
The pharmacokinetics of drugs that are mainly metabolised by UGT1A3 and UGT1A9 could be affected when administered concomitantly with ospemifene and co-administration should be made with caution.
Sočasno jemanje ospemifena in zdravil, ki se v glavnem presnavljajo prek UGT1A3 in UGT1A9, lahko vpliva na farmakokinetiko teh zdravil, zato je pri sočasnem jemanju potrebna previdnost.
The pharmacokinetics of eculizumab was evaluated in Study M07-005 including 7 PNH paediatric patients (aged from 11 to less than 18 years).
Farmakokinetika ekulizumaba je bila ocenjena v študiji M07-005, ki je vključevala 7 pediatričnih bolnikov s PNH (starih od 11 do manj kot 18 let).
The pharmacokinetics of efavirenz in paediatric patients were similar to adults.
Farmakokinetika efavirenza je bila pri pediatričnih bolnikih podobna kot pri odraslih.
The pharmacokinetics of efavirenz, emtricitabine and tenofovir disoproxil fumarate after co-administration of the separate pharmaceutical forms or as Atripla have not been studied in HIV infected patients with renal impairment.
Farmakokinetike efavirenza, emtricitabina in dizoproksiltenofovirijevega fumarata po sočasnem jemanju posameznih farmacevtskih oblik ali v obliki zdravila Atripla niso raziskovali pri bolnikih, okuženih z virusom HIV, ki imajo ledvično okvaro.
The pharmacokinetics of eltrombopag has been studied after administration of eltrombopag to adult subjects with hepatic impairment.
Farmakokinetiko eltrombopaga so raziskovali pri odraslih osebah z okvaro jeter.
The pharmacokinetics of eltrombopag has been studied after administration of eltrombopag to adult subjects with renal impairment.
Farmakokinetiko eltrombopaga so raziskovali pri odraslih osebah z okvaro ledvic.
The pharmacokinetics of eltrombopag have been evaluated in 168 paediatric ITP subjects dosed once daily in two studies, TRA108062/PETIT and TRA115450/PETIT-2.
Farmakokinetiko eltrombopaga so ovrednotili v dveh študijah (TRA108062/PETIT in TRA115450/PETIT-2) pri 168 pediatričnih bolnikih z ITP, ki so zdravilo prejemali enkrat na dan.
The pharmacokinetics of elvitegravir in paediatric subjects have not been established.
Farmakokinetične lastnosti elvitegravirja pri pediatričnih bolnikih niso ugotovljene.
The pharmacokinetics of elvitegravir or cobicistat in paediatric subjects have not been fully established.
Farmakokinetične lastnosti elvitegravirja ali kobicistata pri pediatričnih bolnikih ni v celoti ugotovljena.
The pharmacokinetics of emtricitabine / tenofovir disoproxil have not been studied in subject with hepatic impairment.
Farmakokinetike emtricitabina / dizoproksiltenofovirata niso proučevali pri osebah z jetrno okvaro.
The pharmacokinetics of emtricitabine and tenofovir alafenamide have not been fully evaluated in patients co-infected with HBV and/or HCV.
Farmakokinetične lastnosti emtricitabina in alafenamidtenofovirata pri bolnikih s hkratno okužbo s HBV in/ali HCV niso v celoti ovrednotili.
The pharmacokinetics of emtricitabine and tenofovir alafenamide have not been fully evaluated in patients co-infected with hepatitis B and/or C virus.
Farmakokinetične lastnosti emtricitabina in alafenamidtenofovirata pri bolnikih s hkratno okužbo z virusom hepatitisa B in/ali C niso v celoti ovrednotili.
The pharmacokinetics of emtricitabine have not been studied in non-HBV infected patients with varying degrees of hepatic insufficiency.
Farmakokinetike emtricitabina niso raziskovali pri bolnikih z različnimi stopnjami jetrne insuficience, ki niso okuženi z virusom HBV.
The pharmacokinetics of emtricitabine have not been studied in patients with varying degrees of hepatic insufficiency.
Farmakokinetične lastnosti emtricitabina še niso bile proučevane na bolnikih z različnimi stopnjami jetrne insuficience.
The pharmacokinetics of emtricitabine, rilpivirine and tenofovir alafenamide have not been fully evaluated in patients co-infected with hepatitis B and/or C virus.
Farmakokinetične lastnosti emtricitabina, rilpivirina in alafenamidtenofovirata pri bolnikih s hkratno okužbo z virusom hepatitisa B in/ali C niso v celoti ovrednotili.
The pharmacokinetics of enoxaparin have been studied on the basis of plasma levels of anti-Xa activity and activity of anti-IIb at the recommended doses following single and repeated subcutaneous administration, and following single intravenous injection.
Farmakokinetiko enoksaparina so raziskali zlasti z vidika plazemske aktivnosti anti-Xa in anti-IIa v priporočenih odmerkih po posamični in ponavljajoči se subkutani uporabi ter po posamičnem intravenskem injiciranju.
The pharmacokinetics of enoxaparin have been studied on the basis of plasma levels of anti-Xa activity and activity of anti-IIb at the recommended doses following single and repeated subcutaneous administration, and following single intravenous injection.
Farmakokinetiko enoksaparina so raziskali zlasti z vidika plazemske aktivnosti anti-Xa in anti-IIa, in sicer v priporočenih odmerkih po posamični in ponavljajoči se subkutani uporabi ter po posamičnem intravenskem injiciranju.
The pharmacokinetics of entecavir following a single 1 mg dose in patients (without chronic hepatitis B infection) are shown in the table below:
Farmakokinetika entekavirja po enkratnem 1 mg odmerku pri bolnikih (brez kronične okužbe z virusom hepatitisa B) je prikazana v spodnji tabeli:
The pharmacokinetics of enzalutamide were examined in subjects with baseline mild (N = 6), moderate (N = 8) or severe (N=8) hepatic impairment (Child-Pugh Class A , B or C, respectively) and in 22 matched control subjects with normal hepatic function.
Farmakokinetiko enzalutamida so raziskali pri preiskovancih z izhodiščno blago (Child-Pugh A; n = 6), zmerno (Child-Pugh B; n = 8) ali hudo (Child-Pugh C; n = 8) okvaro jeter in 22 usklajenih primerjalnih preiskovancih z normalnim delovanjem jeter.
The pharmacokinetics of eribulin are characterized by a rapid distribution phase followed by a prolonged elimination phase, with a mean terminal half-life of approximately 40 h.
Za farmakokinetiko eribulina je značilna hitra faza porazdelitve, ki ji sledi podaljšana časa izločanja, s povprečno končno razpolovno dobo približno 40 ur.
The pharmacokinetics of esomeprazole has been studied in doses up to 40 mg b.i.d.
Farmakokinetiko esomeprazola so raziskali z odmerki do 40 mg dvakrat na dan.
The pharmacokinetics of etravirine in 101 treatment-experienced HIV-1 infected paediatric patients, 6 years to less than 18 years of age and weighing at least 16 kg, showed that the administered weight-based dosages resulted in etravirine exposure comparable to that in adults receiving INTELENCE 200 mg b.i.d. (see sections 4.2 and 5.2) when administered at a dose corresponding to mg/kg b.i.d.
Farmakokinetika etravirina je pri 101 s HIV-1 okuženem pediatričnem bolniku (starem od 6 let do manj kot 18 let in s telesno maso najmanj 16 kg) ki se je že zdravil s protiretrovirusnimi zdravili, pokazala da je bila izpostavljenost etravirinu pri odmerkih (odvisnih od telesne mase, ki so ustrezali mg/kg b.i.d,) primerljiva kot pri odraslih, ki so prejemali zdravilo INTELENCE 200 mg b.i.d. (glejte poglavji 4.2 in 5.2).
The pharmacokinetics of fesoterodine have not been evaluated in paediatric patients.
Farmakokinetike fesoterodina pri pediatričnih bolnikih niso ocenili.
The pharmacokinetics of fulvestrant has been evaluated in a clinical trial conducted in 30 girls with Progressive Precocious Puberty associated with McCune Albright Syndrome (see section 5.1).
Farmakokinetika fulvestranta je bila vrednotena v kliničnem preskušanju pri 30 deklicah s progresivno prezgodnjo puberteto, povezano z McCune-Albrightovim sindromom (glejte poglavje 5.1).
The pharmacokinetics of fulvestrant has been evaluated in a single-dose clinical trial conducted in subjects with mild to moderate hepatic impairment (Child-Pugh class A and B).
Farmakokinetika fulvestranta je bila vrednotena v klinični raziskavi z enkratnim odmerkom pri preiskovancih z blago do zmerno jetrno okvaro (A in B stopnjo po Child – Pughovi klasifikaciji).
The pharmacokinetics of gadoversetamide conforms to a two compartment open-model.
Farmakokinetika gadoversetamida ustreza dvodelnemu odprtemu modelu.
The pharmacokinetics of Glivec have been evaluated over a dosage range of 25 to 1,000 mg.
Farmakokinetiko zdravila Glivec so ovrednotili v območju odmerjanja od 25 mg do 1.000 mg.
The pharmacokinetics of guanfacine is similar in children (aged 6 to 12) and adolescent (aged 13 to 17) ADHD patients, and healthy adult volunteers.
Farmakokinetika gvanfacina je podobna pri otrocih (starih 6 do 12 let) in mladostnikih (starih 13 do 17 let) z ADHD in zdravih odraslih prostovoljcih.
The pharmacokinetics of Humalog Mix25 are representative of the individual pharmacokinetic properties of the two components.
Farmakokinetika zdravila Humalog Mix25 predstavlja individualne farmakokinetične lastnosti obeh sestavin.
The pharmacokinetics of Humalog Mix50 are representative of the individual pharmacokinetic properties of the two components.
Farmakokinetika zdravila Humalog Mix50 predstavlja individualne farmakokinetične lastnosti obeh sestavin.
The pharmacokinetics of icatibant has been extensively characterized by studies using both intravenous and subcutaneous administration to healthy volunteers and patients.
Farmakokinetične lastnosti ikatibanta so bile podrobno preučene v študijah, ki so vključevale intravensko in subkutano dajanje ikatibanta zdravim prostovoljcem in bolnikom.
The pharmacokinetics of idelalisib in paediatric subjects have not been established (see section 4.2).
Farmakokinetike idelaliziba pri pediatričnih osebah niso ugotavljali (glejte poglavje 4.2).
The pharmacokinetics of imatinib have been evaluated over a dosage range of 25 to 1,000 mg.
Farmakokinetiko imatiniba so ovrednotili v območju odmerjanja od 25 do 1.000 mg.
The pharmacokinetics of imatinib have been evaluated over a dosage range of 25 to 1,000 mg.
Farmakokinetiko imatiniba so ovrednotili v območju odmerjanja od 25 mg do 1.000 mg.
The pharmacokinetics of imatinib have been evaluated over a dosage range of 25 to 1,000 mg.
Farmakokinetiko imatiniba so ovrednotili v območju odmerjanja od 25 mg do 1000 mg.
The pharmacokinetics of INCRELEX have not been studied in subjects greater than 65 years of age.
Pri osebah, starejših od 65 let, farmakokinetika zdravila INCRELEX ni bila raziskana.
The pharmacokinetics of INCRELEX have not been studied in subjects younger than 12 years of age.
Pri osebah, mlajših od 12 let, farmakokinetika zdravila INCRELEX ni bila raziskana.
The pharmacokinetics of intravenous busulfan was studied in 124 evaluable patients following a 2- hour intravenous infusion for a total of 16 doses over four days.
Farmakokinetiko intravensko uporabljenega busulfana so preučevali na 124 bolnikih, ki jih je bilo možno oceniti, po 2-urni intravenski infuziji do skupno 16 odmerkov v obdobju 4 dni.
The pharmacokinetics of IntronA were studied in healthy volunteers following single 5 million IU/m2 and 10 million IU doses administered subcutaneously, at 5 million IU/m2 administered intramuscularly and as a 30-minute intravenous infusion.
Farmakokinetiko zdravila IntronA so raziskovali pri zdravih prostovoljcih po enkratnih subkutanih odmerkih po 5 milijonov i.e./m2 in 10 milijonov i.e., po intramuskularnem dajanju 5 milijonov i.e./m2 in po 30-minutni intravenski infuziji.
The pharmacokinetics of Kaletra 300/75 mg/m2 twice daily and 230/57.5 mg/m2 twice daily have been studied in a total of 53 paediatric patients, ranging in age from 6 months to 12 years.
Farmakokinetiko zdravila Kaletra 300/75 mg/m2 dvakrat na dan in 230/57,5 mg/m2 dvakrat na dan so raziskali pri skupaj 53 pediatričnih bolnikih, starih od 6 mesecev do 12 let.
The pharmacokinetics of lamivudine are unaffected by hepatic impairment.
Okvara jeter ne vpliva na farmakokinetiko lamivudina.
The pharmacokinetics of ledipasvir, sofosbuvir and GS-331007 in paediatric patients have not been established (see section 4.2).
Farmakokinetike ledipasvirja, sofosbuvirja in GS-331007 pri pediatričnih bolnikih niso ugotavljali (glejte poglavje 4.2).
The pharmacokinetics of LEMTRADA has not been studied in patients aged 55 years and older.
Farmakokinetika zdravila LEMTRADA ni bila preizkušena na bolnikih, starih 55 let in več.
The pharmacokinetics of LEMTRADA were evaluated in a total of 216 patients with RRMS who received intravenous infusions of either 12 mg/day or 24 mg/day for 5 consecutive days, followed by 3 consecutive days 12 months following the initial treatment course.
Farmakokinetika zdravila LEMTRADA je bila ocenjena pri skupno 216 bolnikih z RRMS, ki so prejemali intravenske infuzije bodisi 12 mg/dan bodisi 24 mg/dan 5 zaporednih dni, 12 mesecev po prvem ciklu zdravljenja pa še 3 zaporedne dni.
The pharmacokinetics of levofloxacin following inhalation of Quinsair 240 mg twice daily were investigated in paediatric patients with CF aged 12 years and older and weighing ≥ 30 kg.
Farmakokinetiko levofloksacina po inhaliranju zdravila Quinsair 240 mg dvakrat na dan so preučili pri pediatričnih bolnikih s CF, starih 12 let ali več, s telesno maso ≥ 30 kg.
The pharmacokinetics of Liprolog Mix25 are representative of the individual pharmacokinetic properties of the two components.
Farmakokinetika zdravila Liprolog Mix25 predstavlja individualne farmakokinetične lastnosti obeh sestavin.
The pharmacokinetics of Liprolog Mix50 are representative of the individual pharmacokinetic properties of the two components.
Farmakokinetika zdravila Liprolog Mix50 predstavlja individualne farmakokinetične lastnosti obeh sestavin.
The pharmacokinetics of liraglutide was evaluated in patients with varying degree of hepatic impairment in a single­dose trial.
Farmakokinetiko liraglutida pri bolnikih z različno stopnjo okvare jeter so ocenili v preskušanju z enkratnim odmerkom.
The pharmacokinetics of liraglutide was evaluated in subjects with varying degrees of hepatic impairment in a single-dose trial.
Farmakokinetiko enkratnega odmerka liraglutida so vrednotili v preskušanju pri osebah z različnimi stopnjami okvare jeter.
The pharmacokinetics of lurasidone in paediatric patients aged 6–17 years was generally comparable to those observed in adults.
Pri pediatričnih bolnikih, starih od 6 do 17 let, je bila farmakokinetika v glavnem primerljiva s farmakokinetiko pri odraslih.
The pharmacokinetics of lurasidone is dose-proportional within a total daily dose range of 18.5 mg to 148 mg (equivalent to 20 to 160 mg lurasidone hydrochloride).
Farmakokinetika lurasidona je sorazmerna z odmerkom v celotnem razponu dnevnih odmerkov od 18,5 mg do 148 mg (kar ustreza 20 do 160 mg lurasidonijevega klorida).
The pharmacokinetics of lutropin alfa have been studied in pituitary desensitised female volunteers from 75 IU up to 40,000 IU.
Farmakokinetične lastnosti lutropina alfa so proučevali na hipofizno desenzitiziranih prostovoljkah v odmerku od 75 i.e. do 40.000 i.e.
The pharmacokinetics of naloxegol in the paediatric population has not been studied.
Farmakokinetika naloksegola pri pediatrični populaciji ni raziskana.
The pharmacokinetics of NovoMix 30 have not been investigated in older patients or in patients with renal or hepatic impairment.
Farmakokinetika zdravila NovoMix 30 ni raziskana pri starejših bolnikih in bolnikih z okvaro ledvic ali jeter.
The pharmacokinetics of NovoMix 50 have not been investigated in paediatrics, older patients or in patients with renal or hepatic impairment.
Farmakokinetika zdravila NovoMix 50 ni raziskana pri otrocih, starejših bolnikih in bolnikih z okvaro ledvic ali jeter.
The pharmacokinetics of NovoMix 70 have not been investigated in paediatrics, older patients or in patients with renal or hepatic impairment.
Farmakokinetika zdravila NovoMix 70 ni raziskana pri otrocih, starejših bolnikih in bolnikih z okvaro ledvic ali jeter.
The pharmacokinetics of Numient were evaluated following single doses in healthy subjects and following single and multiple doses in patients with Parkinson’s disease.
Farmakokinetiko zdravila Numient so ocenili po jemanju enkratnih odmerkov pri zdravih preizkušancih ter po jemanju enkratnih in večkratnih odmerkov pri bolnikih s Parkinsonovo boleznijo.
The pharmacokinetics of olanzapine are similar between adolescents and adults.
Farmakokinetika olanzapina je podobna pri mladostnikih in odraslih.
The pharmacokinetics of opicapone was evaluated in elderly subjects (aged 65-78 years old) after 7- day multiple-dose administration of 30 mg.
Farmakokinetiko opikapona so ovrednotili pri starejših osebah (starih od 65 do 78 let) po 7-dnevnem večkratnem odmerjanju 30 mg.
The pharmacokinetics of opicapone was evaluated in healthy subjects and moderate chronic hepatic impaired patients after administration of a single-dose of 50 mg.
Farmakokinetiko opikapona so ovrednotili pri zdravih osebah in pri bolnikih z zmerno kronično okvaro jeter po dajanju enega odmerka 50 mg.
The pharmacokinetics of oral topotecan has not been studied in patients with hepatic impairment (see section 4.2 and 4.4).
Farmakokinetika peroralnega topotekana ni raziskana pri bolnikih z okvaro jeter (glejte poglavji 4.2 in 4.4).
The pharmacokinetics of orally administered telmisartan are non-linear over doses from 20 – 160 mg with greater than proportional increases of plasma concentrations (Cmax and AUC) with increasing doses.
Farmakokinetika peroralnega telmisartana je v razponu odmerkov od 20 to 160 mg nelinearna, koncentracije v plazmi se pri rastočem odmerjanju večajo neproporcionalno (Cmax in AUC).
The pharmacokinetics of orally administered telmisartan are nonlinear over doses from 20-160 mg with greater than proportional increases of plasma concentrations (Cmax and AUC) with increasing doses.
Farmakokinetika peroralnega telmisartana je v razponu odmerkov od 20 to 160°mg nelinearna, koncentracije v plazmi se pri rastočem odmerjanju večajo neproporcionalno (Cmax in AUC).
The pharmacokinetics of oritavancin in patients with severe hepatic impairment (Child-Pugh Class C) has not been evaluated.
Farmakokinetike oritavancina niso ovrednotili pri bolnikih s hudo jetrno okvaro (razred C po Child-Pughu).
The pharmacokinetics of ospemifene has not been evaluated in patients with severe hepatic impairment (Child-Pugh Class score >9).
Farmakokinetike ospemifena niso ovrednotili pri bolnicah s hudo jetrno okvaro (razred po Child- Pughu > 9).
The pharmacokinetics of ospemifene is only mildly affected by mild and moderate hepatic impairment (Child Pugh scores 5-9) when compared to healthy matched controls.
V primerjavi s kontrolno skupino zdravih oseb so ugotovili, da na farmakokinetiko ospemifena le malo vpliva blaga ali zmerna okvara jeter (razred po Child-Pughu 5–9).
The pharmacokinetics of paliperidone following INVEGA administration are dose proportional within the available dose range.
Farmakokinetika paliperidona po zaužitju zdravila INVEGA je sorazmerna odmerku v priporočenem razponu kliničnih odmerkov (od 3 mg do 12 mg).
The pharmacokinetics of palonosetron or netupitant has not been studied in subjects with end-stage renal disease requiring hemodialysis and no data on the effectiveness or safety of Akynzeo in these patients are available.
Farmakokinetike palonosetrona ali netupitanta niso preučili pri osebah s končnim stadijem bolezni ledvic, ki potrebujejo hemodializo, in podatkov o učinkovitosti ali varnosti zdravila Akynzeo pri teh bolnikih ni na voljo.
The pharmacokinetics of parathyroid hormone in patients with severe renal impairment (creatinine clearance of less than 30 mlmin) has not been investigated.
Farmakokinetika obščitničnega hormona pri bolnikih s hudo okvaro ledvic (očistek kreatinina manj kot 30 ml/min) ni raziskana.
The pharmacokinetics of PegIntron have not been evaluated in patients with severe hepatic dysfunction.
Pri bolnikih s hudo jetrno okvaro farmakokinetike zdravila PegIntron niso ocenjevali.
The pharmacokinetics of pembrolizumab was studied in 2,856 patients with metastatic or unresectable melanoma, NSCLC, or carcinoma who received doses in the range of 1 to 10 mg/kg every 2 or weeks.
Farmakokinetiko pembrolizumaba so raziskali pri 2.856 bolnikih z metastatskim ali neoperabilnim melanomom, NSCLC ali karcinomom, ki so prejemali odmerke v razponu od 1 do 10 mg/kg na 2 ali 3 tedne.
The pharmacokinetics of perampanel have been studied in healthy adult subjects (age range 18 to 79), adults and adolescents with partial-onset seizures and primary generalised tonic-clonic seizures, adults with Parkinson’s disease, adults with diabetic neuropathy, adults with multiple sclerosis, and subjects with hepatic impairment.
Farmakokinetiko perampanela so preučili pri zdravih odraslih prostovoljcih (razpon starosti 18 do 79 let), odraslih in mladostnikih z napadi parcialnega izvora in primarnimi generaliziranimi napadi s tonično-kloničnimi krči, odraslih s Parkinsonovo boleznijo, odraslih z diabetično nevropatijo, odraslih z multiplo sklerozo in osebah z jetrno okvaro.
The pharmacokinetics of posaconazole are comparable in men and women.
Farmakokinetika posakonazola je pri moških in ženskah primerljiva.
The pharmacokinetics of posaconazole are comparable in men and women.
Farmakokinetika posakonazola pri ženskah je podobna kot pri moških.
The pharmacokinetics of posaconazole tablets are comparable in men and women.
Farmakokinetika tablet posakonazola je pri moških in ženskah primerljiva.
The pharmacokinetics of raltegravir in infants under 4 weeks of age has not been established.
Pri dojenčkih, mlajših od 4 tednov, farmakokinetike raltegravirja niso določili.
The pharmacokinetics of Rasitrio have not been investigated.
Farmakokinetičnih lastnosti zdravila Rasitrio niso raziskovali.
The pharmacokinetics of regorafenib has not been studied in patients with severe renal impairment or end-stage renal disease.
Farmakokinetike regorafeniba pri bolnikih s hudo okvaro ledvic ali odpovedjo ledvic niso preučevali.
The pharmacokinetics of regorafenib is not influenced by gender.
Spol ne vpliva na farmakokinetiko regorafeniba.
The pharmacokinetics of reslizumab was not significantly different between males and females.
V farmakokinetiki reslizumaba med moškimi in ženskami ni bilo značilnih razlik.
The pharmacokinetics of retigabine in children below 12 years of age have not been investigated.
Farmakokinetika retigabina pri otrocih mlajših od 12 let ni raziskana.
The pharmacokinetics of ribavirin and interferon alfa-2b (dose-normalized) are similar in adults and children or adolescents.
Farmakokinetika ribavirina in interferona alfa-2b (z normaliziranim odmerkom) je podobna pri odraslih in otrocih ali mladostnikih.
The pharmacokinetics of ribavirin and interferon alfa-2b (dose-normalized) are similar in adults and children or adolescents.
Farmakokinetika zdravila Ribavirin BioPartners in interferona alfa-2b (z normaliziranim odmerkom) je podobna pri odraslih in otrocih ali mladostnikih.